Skip to main contentAI and Advanced
/
SENORES · NSEBSE SENSEX74,336.45+0.45%BSE |
NIFTY 5023,217.6+0.43%NSE |
NIFTY BANK56,292.45+0.89%NSE |
NIFTY IT29,087.65-1.58%NSE |
NIFTY AUTO26,893.65+0.51%NSE |
NIFTY FMCG45,559+1.63%NSE |
NIFTY PHARMA26,146.2-0.16%NSE |
NIFTY 50022,532+0.24%NSE |
SE
NSE · Equity shares · Biotechnology & Drugs-39.20 · -2.77%
Senores Pharmaceuticals SENORES
NSE:INR 1,376.9
BSE:INR 1,370.3
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for SENORES
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,416.1
Day rangeINR 1,355.6 — INR 1,425
52-week rangeINR 632.5 — INR 1,599
Volume2.23 L
Market cap6,106.48
P/E46.83
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)632.63
Net Income (INR Cr)115.37
P/E Ratio46.83
EPS26.39
Research path: Interpret Senores Pharmaceuticals's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
SENORESSenores Pharmaceuticals1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,603.81 | 1,226.86 | 621.88 |
| Cash Equivalents | 45.55 | 105.38 | 7.65 |
| Other Liabilities Total | 6.61 | 3.25 | 1.24 |
| Long Term Debt | 194.89 | 162.35 | 133.66 |
| Common Stock Total | 46.05 | 46.05 | 30.51 |
| Other Current Assets Total | 66.03 | 0.1 | 1.37 |
| Total Assets | 1,603.81 | 1,226.86 | 621.88 |
| Current Portof LT Debt/Capital Leases | 133.96 | 112.88 | 83.82 |
| Cash | 114.06 | Not available | 0.2 |
| Total Equity | 933.6 | 786.19 | 204.27 |
| Long Term Investments | 39.11 | 1.33 | 19.49 |
| Retained Earnings(Accumulated Deficit) | 887.55 | 90.04 | 37.35 |
| Total Common Shares Outstanding | 4.61 | 4.61 | 3.33 |
| Tangible Book Valueper Share Common Eq | 119.05 | 122.77 | 15.29 |
| Goodwill Net | 46.55 | 38.21 | 38.21 |
| Total Liabilities | 670.21 | 440.67 | 417.61 |
| Total Debt | 342.03 | 314.75 | 257.64 |
| Short Term Investments | 172.68 | 280.12 | 5.21 |
| Cashand Short Term Investments | 332.29 | 385.5 | 13.06 |
| Total Receivables Net | 324.82 | 270.13 | 192.72 |
| Deferred Income Tax | 0.59 | Not available | Not available |
| Accounts Receivable-Trade Net | 324.82 | 240.81 | 178.06 |
| Property/Plant/Equipment Total-Net | 362.71 | 252.38 | 179.11 |
| Minority Interest | 30.94 | 26.06 | 27.44 |
| Total Current Liabilities | 424 | 240.7 | 247.5 |
| Total Inventory | 89.29 | 56.63 | 37.37 |
| Accounts Payable | 234.72 | 67.22 | 113.01 |
| Other Currentliabilities Total | 55.32 | 25.58 | 18.28 |
| Total Long Term Debt | 208.07 | 170.66 | 141.43 |
| Intangibles Net | 338.79 | 182.6 | 115.19 |
| Other Long Term Assets Total | 4.22 | 19.96 | 15.93 |
| Total Current Assets | 812.43 | 722.43 | 250.91 |
| Capital Lease Obligations | 13.18 | 8.31 | 7.78 |
| Accumulated Depreciation Total | Not available | -21.23 | -7.45 |
| Accrued Expenses | Not available | 3.81 | Not available |
| Other Equity Total | Not available | -4.97 | 2.18 |
| Prepaid Expenses | Not available | 10.07 | 6.39 |
| Additional Paid-In Capital | Not available | 655.07 | 134.23 |
| Property/Plant/Equipment Total-Gross | Not available | 229.44 | 168.79 |
| Notes Payable/Short Term Debt | Not available | 31.21 | 32.39 |
| Note Receivable-Long Term | Not available | 9.95 | 3.04 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio0.39
Price to Sale Ratio9.65
Margins
Operating Margin 12m24.51
Net Profit Margin 12m18.91
Yield
Dividend Yield %0
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk44.32
Analyst consensus
ConsensusStrong Buy
Consensus score1.50
Analyst opinions4
Strong Sell count0
Sell count0
Hold count0
Buy count2
Strong Buy count2
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 45.82%
- FII
- 6.62%
- MF
- 6.56%
- Other
- 41.00%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 19 February 2026Market news · 19 Feb 2026, 7:21 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Senores Pharmaceuticals, ELGI Equipments, Lumax AutoTechnologies, Acutaas Chemicals, and Azad Engineering.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 15 December 2025Market news · 15 Dec 2025, 6:32 am
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today - Indo Borax and Chemicals, Atlanta Electricals, Zota Health Care, CCL Products (India), and Senores Pharmaceuticals.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 1 December 2025Market news · 1 Dec 2025, 6:37 am
Sumeet Bagadia recommends five breakout stocks to buy today - Acutaas Chemicals, Senores Pharmaceuticals, Latent View Analytics, Zaggle Prepaid Ocean Services, and Dr. Agarwal's Health Care.
Breakout stocks to buy or sell: Sumeet Bagadia recommends three shares to buy today — 21 November 2025Market news · 21 Nov 2025, 6:08 am
Sumeet Bagadia recommends five breakout stocks to buy on Friday, 21 November 2025 — Anand Rathi Share and Stock Brokers, Anupam Rasayan India, Azad Engineering, Senores Pharmaceuticals, and PDS.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 27 October 2025Market news · 27 Oct 2025, 7:00 am
Sumeet Bagadia recommends five breakout stocks to buy today: Garware Hi-Tech Films, Cholamandalam Financial Holdings, CreditAccess Grameen, Senores Pharmaceuticals, and Bhageria Industries.
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 9 October 2025Market news · 9 Oct 2025, 6:53 am
Sumeet Bagadia recommends five breakout stocks to buy today: Yatharth Hospital & Trauma Cre Srvcs, Remsons Industries, SeQuent Scientific, SRM Contractors, and Senores Pharmaceuticals.
Corporate actions
Events
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsAudited Results
- annual General MeetingEGM
- board MeetingsTo consider other business matters.
- board MeetingsInter alia, 1. To consider and evaluate proposals for raising funds by way of issue of convertible warrants on preferential basis to the promotors/promoter group.
- board MeetingsQuarterly Results
- annual General MeetingAGM
Rusaka Markets Community
Discussion and sentiment for Senores Pharmaceuticals
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Senores Pharmaceuticals Limited is an India-based company. The Company is engaged in the development and manufacturing of a pharmaceutical product. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Company's products include Acetaminophen + Butalbital Tablet, Candesartan Cilexetil + HCTZ Tablet, Losartan Potassium Tablet, Chlorzoxazone Tablet, Clomiphene Tablet, Deferiprone Tablet, Diltiazem ER Capsule, Enalapril Maleate Tablet, Escitalopram Tablet, Irbesartan Tablet, Olmesartan Medoxomil Tablet and others. It supplies affordable Active Pharmaceutical Ingredients (API) to generic formulations manufacturers. Its product API includes Anastrozole, Aripiprazole, Benfotiamine, Clomiphene Citrate, Desloratadine, Desvenlafaxine Succinate, Fluoxetine Hydrochloride, and others. Its domestic portfolio includes Immunosen - Human Normal Immunoglobulin, Senumin - Human Normal Albumin and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- SENORES
- BSE Code
- 544319
Questions
Stock FAQ
What is the symbol and ISIN of Senores Pharmaceuticals?
Senores Pharmaceuticals has the symbol SENORES and ISIN - INE0RB801010.
What is the current price of Senores Pharmaceuticals?
Senores Pharmaceuticals is currently trading at INR 1,376.90.
What are the year high and year low of Senores Pharmaceuticals?
Senores Pharmaceuticals has a year high of INR 1,599.00 and a year low of INR 632.50.
What is the market capitalization of Senores Pharmaceuticals?
Senores Pharmaceuticals has a market capitalization of INR 6,106.48 crore.
What is the P/E ratio of Senores Pharmaceuticals?
Senores Pharmaceuticals has a P/E ratio of 46.83.
What is the dividend yield of Senores Pharmaceuticals?
Senores Pharmaceuticals has a dividend yield of 0.00%.
How is the financial performance of Senores Pharmaceuticals based on revenue, net income, and EPS?
Senores Pharmaceuticals has revenue of INR 632.63 crore, net income of INR 115.37 crore, and EPS of INR 28.39.
What is the book value of Senores Pharmaceuticals?
Senores Pharmaceuticals has a book value of NA.
What is the debt-to-equity ratio of Senores Pharmaceuticals?
Senores Pharmaceuticals has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Senores Pharmaceuticals?
Senores Pharmaceuticals has a price-to-book ratio of NA and a price-to-sales ratio of 9.65.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.